Miragen therapeutics, inc. (MGEN)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-38,288

-41,873

-42,072

-39,853

-39,671

-32,703

-28,772

-25,595

-24,193

-26,512

-26,100

-24,419

-20,631

-17,274

-14,280

-13,279

-12,317

-11,328

-11,856

-9,091

-9,818

-7,890

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Unpaid common stock issuance costs included in prepaid expenses and other assets, accounts payable, and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Issuance of common stock under subscription agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

330

0

0

0

-

-

-

-

Share-based compensation expense

3,616

3,970

3,904

3,998

3,907

3,679

3,458

3,169

2,780

2,409

1,762

1,128

575

198

886

1,679

2,349

3,015

0

0

0

-

-

-

-

Implementation of ASC 842 and other non-cash lease expenses

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

309

340

359

373

374

376

292

222

158

94

118

136

148

158

0

0

0

-

-

-

-

-

-

-

-

Depreciation and amortization

327

300

315

262

304

300

273

290

296

300

315

324

333

341

300

259

220

184

175

162

153

144

0

0

0

Loss on sale of equipment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premiums and discounts on available-for-sale securities

251

432

597

680

598

416

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash interest on note payable  related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

132

109

87

495

1,007

0

0

0

Changes in operating assets and liabilities:
Accounts receivable

-2

84

-403

-873

-4,803

-1,432

747

659

4,532

1,436

626

-199

337

20

-144

551

-264

-694

-1,003

-778

-576

94

0

0

0

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

132

343

205

-178

0

0

0

Prepaid expenses and other assets

-860

-126

-492

47

-274

-51

932

1,302

711

724

600

254

897

426

346

517

139

-28

-10

-321

16

-191

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-519

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

989

525

363

771

-243

-335

784

-148

-365

-101

280

-288

175

292

0

0

0

-

-

-

-

-

-

-

-

Accrued and other liabilities

-312

1,084

433

318

-423

791

-53

-697

-786

-2,205

447

1,691

1,928

2,211

0

0

0

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

633

286

538

775

383

0

0

0

Lease termination/abandonment payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

248

319

318

319

376

0

0

0

Net cash used in operating activities

-32,706

-36,056

-36,425

-33,960

-31,292

-26,844

-25,912

-24,773

-27,345

-28,167

-24,211

-21,383

-18,768

-14,755

-12,767

-12,236

-9,959

-6,898

-6,596

-5,123

-3,407

-2,213

0

0

0

Cash flows from investing activities:
Purchases of short-term investments

8,907

32,690

56,548

58,393

86,245

62,462

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

42,000

61,000

87,000

72,000

54,000

33,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in reverse merger

-

-

-

-

-

-

-

-

-

1,280

1,280

1,280

1,280

0

0

0

0

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

47

84

135

325

387

445

428

286

297

246

222

183

189

250

263

271

184

123

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

33,047

28,226

30,317

13,282

-32,632

-29,907

-39,032

-33,081

-297

1,034

2,068

5,106

1,091

-250

-1,273

-4,252

-156

-95

0

0

0

-

-

-

-

Cash flows from financing activities:
Proceeds from the sale of common stock and warrants

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

4,021

3,749

13,095

13,095

8,605

16,264

6,644

0

0

0

Payment of issuance costs associated with the sale of common stock

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Payments of principal on note payable

3,333

2,333

0

0

0

-

-

-

-

4,667

1,833

1,333

833

333

0

0

0

-

-

-

-

-

-

-

-

Proceeds from stock purchases under employee stock purchase plan

42

110

110

216

216

242

242

220

220

110

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Stock Options Exercised

113

100

106

69

88

200

259

298

323

300

433

361

302

213

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of note payable/amounts due to related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

795

0

0

0

Shares repurchased to satisfy tax withholding obligation for restricted stock awards

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

363

0

0

0

-

-

-

-

Repayment of capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

76

67

46

44

42

0

0

0

Net cash provided by financing activities

17,567

70

-735

1,283

4,020

41,916

53,839

54,921

51,468

52,470

40,350

54,235

54,990

15,874

16,111

4,014

3,404

12,706

12,665

8,213

16,888

7,397

0

0

0

Net increase (decrease) in cash and cash equivalents

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

18,207

37,958

37,313

869

2,071

-12,474

-6,711

5,713

5,736

2,752

13,163

4,910

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information
Cash paid for interest

436

511

537

534

513

489

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

159

161

164

0

0

0

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax

-

-

-

-

-

-3

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of public offering costs

32

3

1

2

9

55

55

54

47

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized Gain (Loss) on Investments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unpaid common stock issuance costs included in current liabilities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

-

76,981

76,981

76,981

76,981

0

0

0

0

-

-

-

-

-

-

-

-

Liabilities assumed, net of non-cash assets received in reverse merger

-

-

-

-

-

-

-

-

-

1,076

1,076

1,076

1,076

0

0

0

0

-

-

-

-

-

-

-

-

Transfer of common stock issuance costs from prepaid expenses and other current assets to equity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Reclassification of preferred stock warrant (accrued liability) to common stock warrant (equity)

-

-

-

-

-

-

-

-

-

51

51

51

51

0

0

0

0

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

5

17

30

42

49

0

0

0

-

-

-

-

-

-

-

-

At-the-market
Proceeds from the sale of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of issuance costs associated with the sale of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering
Proceeds from the sale of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of issuance costs associated with the sale of common stock

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-